Sinovac Biotech Ltd

(NASDAQ:SVA)

Latest On Sinovac Biotech Ltd (SVA):

Date/Time Type Description Signal Details
2022-08-03 11:16 ESTNewsSinovac's COVID shot approved for use in children aged 6 months to 3 years in Hong KongN/A
2022-07-19 22:49 ESTNewsSinovac begins late-stage trial of influenza vaccine in ChileN/A
2022-07-14 11:22 ESTNewsSinovac COVID-19 vaccine gets emergency use nod in Brazil for children aged 3-5 yearsN/A
2022-06-27 16:22 ESTNewsSinovac Biotech COVID-19 vaccine conditionally registered in South AfricaN/A
2022-05-17 17:39 ESTNewsCEPI to fund Sabin Vaccine Institute trial to see efficacy of lower doses of COVID boostersN/A
2022-05-02 09:21 ESTNewsSinovac Biotech GAAP EPS of $74.27, revenue of $19.4BN/A
2022-04-18 06:29 ESTNewsSinovac Biotech's Omicron-specific vaccine cleared for clinical trial in Hong KongN/A
2022-04-08 05:27 ESTNewsSupply chain on watch as Shanghai lockdown grows in severityN/A
2022-03-25 00:55 ESTNewsSinovac booster shows 98% protection against death/severe COVID in people over 60 in studyN/A
2022-01-25 02:45 ESTNewsAstraZeneca, Pfizer/ BioNTech or J&J shots found to boost effect of Sinovac COVID-19 vaccineN/A
2021-12-31 11:54 ESTNewsSinovac Biotech reports 1H resultsN/A
2021-12-23 20:56 ESTNewsThree doses of Sinovac's COVID-19 vaccine fail to protect against Omicron variant: StudyN/A
2021-12-12 12:27 ESTNewsGreatly Transformed Sinovac Set To Reawaken On Wall Street?N/A
2021-10-12 13:29 ESTNewsWHO recommends an additional COVID-19 vaccine for immunocompromised peopleN/A
2021-09-09 12:31 ESTNewsSinovac’s COVID-19 vaccine booster shot shows better neutralization breadth to VOCsN/A
2021-09-08 16:26 ESTNewsSinovac's COVID-19 vaccine gets emergency use approval in ChileN/A
2021-09-07 20:54 ESTNewsSinovac's COVID-19 booster shot reverses drop in antibody activities against Delta: StudyN/A
2021-09-03 23:12 ESTNewsChina is struggling to expand COVID-19 vaccination drive - officialN/A
2021-08-17 21:20 ESTNewsSinovac COVID-19 vaccine is linked to higher risk of Bell's Palsy - studyN/A
2021-08-10 12:23 ESTNewsSinovac COVID vaccine demonstrates strong immune response with booster shotN/A
2021-07-27 16:55 ESTNewsSinovac's COVID-19 vaccine antibodies fade after six months: StudyN/A
2021-07-22 03:01 ESTNewsWHO seeks more data on Sinovac Biotech’s COVID-19 vaccine - WSJN/A
2021-07-22 02:58 ESTNewsPfizer/ BioNTech and AstraZeneca to dominate global COVID-19 vaccine supply in 2021N/A
2021-07-22 02:58 ESTNewsBrazilian study indicates Sinovac shot benefit when majority of population vaccinatedN/A
2021-07-22 02:57 ESTNewsSinovac obtains WHO emergency use listing for COVID-19 shotN/A
2021-07-22 02:36 ESTNewsSome Chinese vaccines less effective against COVID-19 Delta variant - ReutersN/A
2021-07-22 02:33 ESTNewsSinovac’s COVID-19 vaccine shows potential to induce strong immune responses in children aged 3 to 17N/A
2021-07-22 02:26 ESTNewsSome countries consider booster shots for those who received Sinovac COVID-19 shotN/A
2021-07-22 02:23 ESTNewsSinovac to supply 380M doses of COVID-19 vaccine to COVAXN/A
2021-07-22 02:23 ESTNewsChinese COVID-19 shots have nearly 70% efficacy against Delta variant, scientist saysN/A
2021-07-22 02:20 ESTNewsPfizer/BioNTech, Moderna vaccine effect impacted by COVID-19 Lambda variantN/A
2021-07-22 02:15 ESTNewsPfizer/BioNTech COVID-19 shot triggers higher antibody levels compared to Sinovac vaccine: new studyN/A
2021-05-05 03:41 ESTNewsSinovac’s COVID-19 shot undergoes rolling review in EuropeN/A
2021-04-16 20:02 ESTNewsSinovac vaccine 67% effective against symptomatic infection in real-world study - ReutersN/A
2021-02-18 22:43 ESTNewsSinovac’s COVID-19 vaccine is said to be effective against new variantsN/A
2021-02-10 19:05 ESTNewsSinovac's COVID-19 vaccine wins conditional marketing authorization in ChinaN/A
2021-02-06 08:03 ESTNewsSinovac’s announces late-stage data for COVID-19 vaccine candidateN/A
2021-01-18 00:32 ESTNewsAstraZeneca and Sinovac COVID-19 shots get emergency nod in BrazilN/A
2021-01-16 16:39 ESTFinancialsCompany financials have been released.Neutral
2021-01-15 12:44 ESTFinancialsCompany financials have been released.Neutral
2021-01-15 12:44 ESTAnalyst RatingThe Analyst Target Price has increased from $0 to $6.Neutral
2021-01-13 19:11 ESTNewsPhilippines to obtain additional 20M doses of AstraZeneca's COVID-19 jabN/A
2021-01-13 19:11 ESTNewsSinovac's COVID-19 shot demonstrates four different protection rates, Brazil results shows 50.4% efficacyN/A
2021-01-01 13:15 ESTNewsSinopharm gets conditional approval for COVID-19 vaccine in ChinaN/A
2020-12-22 09:11 ESTNewsSinovac’s COVID-19 shot effective in Brazil trials - WSJN/A
2020-12-14 08:12 ESTNewsSingapore approves Pfizer-BioNTech's COVID-19 jabN/A
2020-12-11 12:18 ESTNewsHong Kong secures deals for 15M COVID-19 shots, with first lot arriving in JanuaryN/A
2020-12-07 11:04 ESTNewsSinovac secures ~$500M funding for COVID-19 vaccine developmentN/A
2020-12-07 11:04 ESTNewsSinovac Biotech reports Q3 resultsN/A
2020-11-19 00:25 ESTNewsSinovac's COVID-19 vaccine 'successful' in mid-stage trialsN/A

About Sinovac Biotech Ltd (SVA):

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People's Republic of China.

SVA Quotes by TradingView

See Advanced Chart

General

  • Name Sinovac Biotech Ltd
  • Symbol SVA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 910
  • Fiscal Year EndDecember
  • IPO Date2003-11-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.sinovacbio.com
View More

Valuation

  • Trailing PE 38.51
  • Price/Sales (Trailing 12 Mt.) 1.83
  • Price/Book (Most Recent Quarter) 1.82
  • Enterprise Value Revenue 1.12
  • Enterprise Value EBITDA 5.6
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Profit Margin 9%
  • Operating Margin 18%
  • Return on Assets 6%
  • Return on Equity 13%
  • Revenue 264.28 million
  • Earnings Per Share $0.17
  • Revenue Per Share $2.67
  • Gross Profit 213.58 million
  • Quarterly Earnings Growth 79.4%
View More

Highlights

  • Market Capitalization 460.25 million
  • EBITDA 51.39 million
  • Analyst Target Price $6
  • Book Value Per Share $3.10
View More

Share Statistics

  • Shares Outstanding 98.9 million
  • Shares Float 43.95 million
  • % Held by Insiders 4346%
  • % Held by Institutions 33.94%
  • Shares Short 200105
  • Shares Short Prior Month 200105
View More

Technicals

  • Beta 0.05
  • 52 Week High $6.47
  • 52 Week Low $6.47
  • 50 Day Moving Average 6.47
  • 200 Day Moving Average 6.47
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Sinovac Biotech Ltd (SVA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Sinovac Biotech Ltd (SVA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-12-07$115.45 million$0.08
2020-06-302020-09-30$52.33 million$0.10
2020-03-312020-06-30$N/A-$0.05
2019-12-312020-03-31$N/A-$0.07$0.00
2019-09-302019-12-31$64.34 million$0.19
2019-06-302019-09-30$64.05 million$0.06
2019-03-312019-06-30$36.55 million$0.11$0.00
2018-12-312019-03-31$53.58 million$0.01$0.00
2018-09-302018-12-31$53.58 million-$0.02$0.00
2018-06-302018-09-30$46.45 million$0.12$0.00
2018-03-312018-06-30$47.34 million$0.10$0.00
2017-12-312018-03-31$107.44 million$0.14$0.00
2017-09-302017-12-31$53.72 million$0.13$0.00
2017-06-302017-09-30$66.91 million$0.13$0.00
2017-03-312017-06-30$33.45 million$0.10
2016-12-312017-03-31$31.37 million$0.10$0.00
2016-09-302016-12-31$28.74 million$0.08
2016-06-302016-09-30$1.38 million$0.06
2016-03-312016-06-30$10.95 million-$0.17
2015-12-312016-03-31$22.95 million-$0.02$0.00
2015-09-302015-12-31$16.76 million$-0.00-$0.0299.5%
2015-06-302015-09-30$18.49 million-$0.03-$0.01-200%
2015-03-312015-06-30$9.21 million$0.04-$0.02300%
2014-12-312015-03-31$20.32 million-$0.04$0.00
2014-09-302014-11-14$17.15 million$0.00-$0.01116%
2014-06-302014-09-30$12.09 million$0.00
2014-03-312014-06-30$13.55 million-$0.04-$0.03-34.67%
2013-12-312014-03-31$22.95 million$0.00-$0.01101%
2013-09-302013-12-31$22.08 million$0.10-$0.02598%
2013-06-302013-09-30$17.45 million$0.04-$0.06166.67%
2013-03-312013-06-30$10.05 million$0.02-$0.10120%
2012-12-312013-03-31$19.59 million-$0.04$0.00
2012-09-302012-12-31$14.29 million-$0.08-$0.03-179%
2012-06-302012-09-30$9.37 million-$0.05-$0.1045.4%
2012-03-312012-06-30$5.97 million-$0.02-$0.1384.62%
2011-12-312012-03-31$21.14 million-$0.10$0.03-442.67%
2011-09-302011-12-31$15.36 million$0.05$0.02148%
2011-06-302011-09-30$15.66 million-$0.04-$0.01-300%
2011-03-312011-06-30$4.68 million$0.02$0.01100%
2010-12-312011-03-31$9.14 million-$0.05$0.02-356.5%
2010-09-302010-11-15$9.55 million-$0.01$0.02-150%
2010-06-302010-08-16$10.26 million$0.02$0.01100%
2010-03-312010-04-06$4.44 million$0.21$0.25-16%
2009-09-302009-11-15$21.23 million$0.12$0.0850%
2009-06-302009-08-19$20.02 million$0.14$0.011300%
2009-03-312009-05-15$6.57 million$0.00
2008-09-302008-11-18$8.75 million$0.02$0.03-33.33%
2008-06-302008-08-13$16.52 million$0.08$0.080%
2008-03-312008-05-16$8.86 million$0.04
2007-12-312008-03-31$9.2 million$0.05$0.050%
2007-09-302007-12-11$10.83 million$0.05
2007-06-302007-06-30$9.54 million$0.09

Sinovac Biotech Ltd (SVA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Sinovac Biotech Ltd (SVA) Chart:

Sinovac Biotech Ltd (SVA) News:

Below you will find a list of latest news for Sinovac Biotech Ltd (SVA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Sinovac Biotech Ltd (SVA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Sinovac Biotech Ltd (SVA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920078469/0001104659-20-078469-index.htm
2018-01-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1084201/000000000018002196/0000000000-18-002196-index.htm
2017-02-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1084201/000090221917000376/0000902219-17-000376-index.htm
2018-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1084201/000090221918000018/0000902219-18-000018-index.htm
2018-07-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1084201/000090445418000467/0000904454-18-000467-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1084201/000092963819000368/0000929638-19-000368-index.htm
2019-11-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465919064902/0001104659-19-064902-index.htm
2019-12-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465919076914/0001104659-19-076914-index.htm
2020-02-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920023900/0001104659-20-023900-index.htm
2020-02-218-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1084201/000110465920023911/0001104659-20-023911-index.htm
2020-04-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920046372/0001104659-20-046372-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920047952/0001104659-20-047952-index.htm
2020-04-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920054500/0001104659-20-054500-index.htm
2020-05-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920057275/0001104659-20-057275-index.htm
2020-05-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920063161/0001104659-20-063161-index.htm
2020-05-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920065137/0001104659-20-065137-index.htm
2020-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920072241/0001104659-20-072241-index.htm
2020-06-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920073145/0001104659-20-073145-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920076447/0001104659-20-076447-index.htm
2020-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920078469/0001104659-20-078469-index.htm
2020-07-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920080953/0001104659-20-080953-index.htm
2020-08-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920098489/0001104659-20-098489-index.htm
2020-08-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920100245/0001104659-20-100245-index.htm
2020-09-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920107664/0001104659-20-107664-index.htm
2020-09-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920107666/0001104659-20-107666-index.htm
2020-09-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000110465920109473/0001104659-20-109473-index.htm
2016-08-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420416120848/0001144204-16-120848-index.htm
2016-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420416127478/0001144204-16-127478-index.htm
2016-10-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420416128847/0001144204-16-128847-index.htm
2016-11-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420416132234/0001144204-16-132234-index.htm
2016-12-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420416141104/0001144204-16-141104-index.htm
2017-02-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417006584/0001144204-17-006584-index.htm
2017-03-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417016364/0001144204-17-016364-index.htm
2017-03-248-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1084201/000114420417016366/0001144204-17-016366-index.htm
2017-05-01NT 20-FNotification of inability to timely file Form 20-Fhttps://www.sec.gov/Archives/edgar/data/1084201/000114420417023450/0001144204-17-023450-index.htm
2017-05-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417027949/0001144204-17-027949-index.htm
2017-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417033924/0001144204-17-033924-index.htm
2017-06-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1084201/000114420417034228/0001144204-17-034228-index.htm
2017-06-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1084201/000114420417034230/0001144204-17-034230-index.htm
2017-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417035049/0001144204-17-035049-index.htm
2017-06-308-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1084201/000114420417035055/0001144204-17-035055-index.htm
2017-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417042642/0001144204-17-042642-index.htm
2017-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417056214/0001144204-17-056214-index.htm
2017-11-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417057299/0001144204-17-057299-index.htm
2017-11-2220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1084201/000114420417060660/0001144204-17-060660-index.htm
2017-11-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417060691/0001144204-17-060691-index.htm
2017-11-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417061585/0001144204-17-061585-index.htm
2017-12-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417061780/0001144204-17-061780-index.htm
2017-12-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417061781/0001144204-17-061781-index.htm
2017-12-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420417065708/0001144204-17-065708-index.htm
2018-01-05SC 13E3Going private transaction by certain issuershttps://www.sec.gov/Archives/edgar/data/1084201/000114420418000917/0001144204-18-000917-index.htm
2018-01-30SC 13E3/AGoing private transaction by certain issuershttps://www.sec.gov/Archives/edgar/data/1084201/000114420418004421/0001144204-18-004421-index.htm
2018-01-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1084201/000114420418004422/0001144204-18-004422-index.htm
2018-02-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418006114/0001144204-18-006114-index.htm
2018-03-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418012931/0001144204-18-012931-index.htm
2018-03-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418013074/0001144204-18-013074-index.htm
2018-03-068-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1084201/000114420418013077/0001144204-18-013077-index.htm
2018-03-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418014790/0001144204-18-014790-index.htm
2018-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418017019/0001144204-18-017019-index.htm
2018-04-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418021255/0001144204-18-021255-index.htm
2018-04-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418021267/0001144204-18-021267-index.htm
2018-04-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418021870/0001144204-18-021870-index.htm
2018-04-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418022874/0001144204-18-022874-index.htm
2018-04-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418022879/0001144204-18-022879-index.htm
2018-04-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418023594/0001144204-18-023594-index.htm
2018-04-30NT 20-FNotification of inability to timely file Form 20-Fhttps://www.sec.gov/Archives/edgar/data/1084201/000114420418023852/0001144204-18-023852-index.htm
2018-05-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418024580/0001144204-18-024580-index.htm
2018-05-08NT 20-F/ANotification of inability to timely file Form 20-Fhttps://www.sec.gov/Archives/edgar/data/1084201/000114420418025875/0001144204-18-025875-index.htm
2018-05-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418026108/0001144204-18-026108-index.htm
2018-05-1120-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1084201/000114420418027303/0001144204-18-027303-index.htm
2018-05-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418027622/0001144204-18-027622-index.htm
2018-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418033664/0001144204-18-033664-index.htm
2018-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418035710/0001144204-18-035710-index.htm
2018-07-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418037077/0001144204-18-037077-index.htm
2018-07-038-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1084201/000114420418037079/0001144204-18-037079-index.htm
2018-07-23SC 13E3/AGoing private transaction by certain issuershttps://www.sec.gov/Archives/edgar/data/1084201/000114420418039200/0001144204-18-039200-index.htm
2018-08-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418045446/0001144204-18-045446-index.htm
2018-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418049587/0001144204-18-049587-index.htm
2018-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418053084/0001144204-18-053084-index.htm
2018-10-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418053908/0001144204-18-053908-index.htm
2018-10-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418054099/0001144204-18-054099-index.htm
2018-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418054648/0001144204-18-054648-index.htm
2018-11-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418058119/0001144204-18-058119-index.htm
2018-11-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418062066/0001144204-18-062066-index.htm
2018-12-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418064346/0001144204-18-064346-index.htm
2018-12-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420418065492/0001144204-18-065492-index.htm
2019-02-228-A12GRegistration of securities [Section 12(g)]https://www.sec.gov/Archives/edgar/data/1084201/000114420419009655/0001144204-19-009655-index.htm
2019-02-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420419009657/0001144204-19-009657-index.htm
2019-02-228-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1084201/000114420419009658/0001144204-19-009658-index.htm
2019-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420419013112/0001144204-19-013112-index.htm
2019-04-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420419019580/0001144204-19-019580-index.htm
2019-04-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420419019804/0001144204-19-019804-index.htm
2019-04-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420419022195/0001144204-19-022195-index.htm
2019-07-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420419034351/0001144204-19-034351-index.htm
2019-08-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1084201/000114420419040319/0001144204-19-040319-index.htm
2017-07-07SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1084201/000121465917004388/0001214659-17-004388-index.htm
2018-03-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1084201/000121465918002332/0001214659-18-002332-index.htm
2019-04-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1084201/000156459019013766/0001564590-19-013766-index.htm
2020-04-3020-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1084201/000156459020020204/0001564590-20-020204-index.htm
2018-07-11SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1084201/000161577418006389/0001615774-18-006389-index.htm
2018-07-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1084201/000161577418006725/0001615774-18-006725-index.htm
2018-08-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1084201/000161577418008663/0001615774-18-008663-index.htm